Want to see AZTR full AI Analyst Report?
Top Page
Azitra Inc
(AZTR)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.13
▼(-26.67% Downside)
Action:Reiterated
Date:10/01/26
The score is weighed down primarily by weak financial performance (minimal revenue, ongoing losses, and significant/volatile cash burn), reinforced by bearish technical trend signals (below major moving averages with negative MACD and low RSI). Corporate events are a partial offset (trial progression and regained listing compliance), but valuation support is limited given negative earnings and no dividend.
Positive Factors
Clinical Trial Progress
Advancing from Cohort 1 to Cohort 2 after safety review is a tangible clinical-development milestone. Continued enrollment can generate safety and preliminary efficacy data, strengthening the program’s potential relevance in a defined dermatology supportive-care indication.
Negative Factors
Pre-Revenue Operations
The absence of recurring revenue leaves Azitra dependent on future clinical success, partnerships, licensing, or external financing to support operations. Persistent sizable losses also indicate that the business has not yet established commercial scale or operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Trial Progress
Advancing from Cohort 1 to Cohort 2 after safety review is a tangible clinical-development milestone. Continued enrollment can generate safety and preliminary efficacy data, strengthening the program’s potential relevance in a defined dermatology supportive-care indication.
Read all positive factors
Azitra Inc (AZTR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.88M
Dividend YieldN/A
Average Volume (3M)1.06M
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue GrowthN/A
EPS Growth78.16%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.30
Shares Outstanding60,603,740
10 Day Avg. Volume914,824
30 Day Avg. Volume1,057,689
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap-0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.60
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)N/A
Azitra Inc Business Overview & Revenue Model
Company Description
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The ...
How the Company Makes Money
Azitra’s revenue model is primarily biotech-style and is expected to rely on (1) out-licensing or partnering its drug candidates and platform with larger pharmaceutical/dermatology companies in exchange for upfront payments, development and regula...
Azitra Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
5
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 7.50K | 686.00K | 284.00K | 110.00K |
| Gross Profit | 0.00 | 0.00 | 7.50K | 686.00K | 284.00K | 110.00K |
| EBITDA | -5.10M | -10.49M | -8.50M | -10.67M | -10.02M | -8.79M |
| Net Income | -12.27M | -10.96M | -8.97M | -11.28M | -10.68M | -8.94M |
Balance Sheet | ||||||
| Total Assets | 8.92M | 5.03M | 7.36M | 5.12M | 7.17M | 10.20M |
| Cash, Cash Equivalents and Short-Term Investments | 6.73M | 2.07M | 4.55M | 1.80M | 3.49M | 8.04M |
| Total Debt | 410.05K | 422.08K | 555.51K | 885.95K | 7.73M | 992.02K |
| Total Liabilities | 1.58M | 1.22M | 1.66M | 2.20M | 43.43M | 35.97M |
| Stockholders Equity | 7.33M | 3.80M | 5.70M | 2.91M | -36.26M | -25.77M |
Cash Flow | ||||||
| Free Cash Flow | -11.29M | -11.41M | -10.56M | -7.68M | -8.69M | -8.72M |
| Operating Cash Flow | -11.11M | -11.22M | -10.18M | -7.36M | -8.35M | -8.07M |
| Investing Cash Flow | -279.62K | -182.91K | -379.25K | -318.26K | -336.76K | -652.27K |
| Financing Cash Flow | 17.07M | 8.92M | 13.32M | 5.98M | 4.13M | 992.86K |
Azitra Inc Technical Analysis
Negative
0.18
Price Trends
0.15
Negative
0.17
Negative
0.20
Negative
Market Momentum
>-0.01
Positive
37.79
Neutral
19.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTR, the sentiment is Negative. The current price of 0.18 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.15, and below the 200-day MA of 0.20, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.79 is Neutral, neither overbought nor oversold. The STOCH value of 19.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTR.
Azitra Inc Risk Analysis
Azitra Inc disclosed 47 risk factors in its most recent earnings report. Azitra Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Azitra Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $7.88M | -0.10 | -205.45% | ― | ― | 78.16% | |
| ― | $2.19M | -0.14 | -144.23% | ― | ― | 86.26% | |
44 Neutral | $6.58M | -0.09 | -168.05% | ― | ― | 87.05% | |
43 Neutral | $7.31M | -0.38 | -134.73% | ― | -60.74% | 66.05% | |
33 Underperform | $2.90M | -0.07 | -91.95% | ― | -51.33% | 99.22% |
* Healthcare Sector Average
AZTR
Azitra Inc
0.13
-0.61
-82.09%
OGEN
Oragenics
0.50
-0.89
-64.10%
INM
InMed Pharmaceuticals
1.33
-1.13
-45.93%
ENVB
Enveric Biosciences
1.50
-6.75
-81.87%
SPRC
SciSparc Ltd.
4.64
-34.78
-88.23%
ONCO
Onconetix
0.60
-190.40
-99.69%
Azitra Inc Corporate Events
Business Operations and StrategyProduct-Related Announcements
Azitra Advances ATR04-484 Trial to Second Cohort
Positive
Oct 1, 2026
On October 1, 2026, Azitra Inc. reported completion of Cohort 1 in its Phase 1/2 clinical trial of ATR04-484, a topical live biotherapeutic being studied for EGFR inhibitor-associated skin rash in adult cancer patients. After reviewing safety data...
Private Placements and FinancingRegulatory Filings and Compliance
Azitra Launches At-the-Market Equity Offering Program
Neutral
Sep 28, 2026
On September 28, 2026, Azitra, Inc. entered into a sales agreement with A.G.P./Alliance Global Partners allowing the company, at its discretion, to issue and sell up to $3,503,232 of its common stock through an at-the-market equity program. The sh...
Business Operations and Strategy
Azitra to Present Corporate Update at Investment Conference
Positive
Sep 8, 2026
On September 8, 2026, Azitra Inc. announced that co-founder and chief operating officer Travis Whitfill will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference in New York, held September 14-16, 2026. Th...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Azitra Regains NYSE American Listing Compliance Status
Positive
Aug 21, 2026
Azitra, Inc., a clinical-stage biopharmaceutical group specializing in precision dermatology, cosmeceuticals and biotech applications, is developing key programs including ATR-COSF for cosmetic and skincare uses and ATR-04 for EGFR inhibitor-assoc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.